Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioGenesis upbeat despite poor sales

This article was originally published in Clinica

Executive Summary

Orthopaedic company Biomet's quarterly profits missed analysts' expectations by one cent. The company is continuing to build its direct sales operations, which has affected its expenses in the quarter. Biomet is building up its Japanese direct sales operations and has also added to its own sales force by the acquisition last November of Synthes-Stratec's reconstructive products division (see Clinica No 983, p 15). In addition, it has added 18 sales representatives to its EBI division. The Warsaw, Indiana-based company had reconstructive product sales of $185 million in the quarter, up 17%, fixation product sales of $54 million, a 2% increase, and spinal product sales of $32 million, up 30%. Sales of the company's "other products" were up 19% to $34 million. The company has authorised the repurchase of $100 million of shares. This is in addition to a similar-sized repurchase plan announced in December 2001. "We continue to believe that our shares represent an excellent investment for the company," said Dane Miller, CEO. "Our continued high levels of earnings have produced cash in excess of our immediate needs and we view this programme as an investment in our future."

You may also be interested in...



Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar

On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.

Everlywell Raises $175M To Expand Consumer Lab Testing, Digital Health

The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.

UK Faces Distribution Challenges With Pfizer/BioNTech Vaccine

New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.

Topics

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel